Subcutaneous (SubQ) injection is the most common administration route for research peptides. Done correctly, it's straightforward — a short needle, a small volume, injected into fatty tissue just under the skin. Done incorrectly, it causes unnecessary pain, bruising, and inconsistent absorption. This guide covers everything: needle selection, injection sites, technique, and troubleshooting.
Research context only. The peptides and compounds discussed on WolveStack are research chemicals not approved for human use by the FDA. Nothing on this page constitutes medical advice. Consult a qualified healthcare professional before use.
28–31 gauge is standard. 29G is the most common choice — thin enough to cause minimal pain, thick enough that drawing from a vial doesn't take forever. 31G is the thinnest commonly available and is virtually painless but draws slower. The SubQ layer is also largely free of major blood vessels and nerves, making it significantly more forgiving than intramuscular injection for a first-time injector. Products ship from the USA with published purity certificates. The abdomen is the most commonly used SubQ injection site — specifically the area 2 inches to either side of the navel. It's well-vascularised with a relatively slow but consistent blood supply, which means peptides injected here are absorbed gradually into systemic circulation rather than in a rapid bolus. The standard needle length for SubQ is 5/16 inch (8mm) or 1/2 inch (12.7mm), 28–31 gauge.
What SubQ Injection Actually Does
Subcutaneous tissue sits just below the dermis and above the muscle layer. It's well-vascularised with a relatively slow but consistent blood supply, which means peptides injected here are absorbed gradually into systemic circulation rather than in a rapid bolus. For most peptides — including BPC-157, TB-500, GHK-Cu, and GH secretagogues — this slow absorption is actually desirable, producing a sustained plasma concentration rather than a sharp spike.
The SubQ layer is also largely free of major blood vessels and nerves, making it significantly more forgiving than intramuscular injection for a first-time injector. The standard needle length for SubQ is 5/16 inch (8mm) or 1/2 inch (12.7mm), 28–31 gauge. Most peptide researchers use 29G or 31G half-inch insulin syringes.
Common Injection Sites
The abdomen is the most commonly used SubQ injection site — specifically the area 2 inches to either side of the navel. Abdominal SubQ tissue is thick, accessible, and absorbs well. It's also easy to self-administer.
Other viable sites include: the outer thigh (lateral quadriceps region), the lateral upper arm, and the lower back / flank area. Rotating between sites prevents lipohypertrophy (fatty lumps that can develop from repeated injection at the same spot) and maintains consistent absorption.
Sites to avoid: directly over the navel, directly over veins or arteries (look before injecting), areas with active bruising or infection, and the inner thigh where skin is thin and movement causes friction.
Step-by-Step Injection Protocol
| Step | Action | Notes |
|---|---|---|
| 1 | Wash hands thoroughly | 30 seconds, soap and water |
| 2 | Wipe injection site with alcohol swab | Let dry 30 seconds — wet alcohol stings |
| 3 | Pinch skin between thumb and forefinger | Creates a fold of SubQ tissue |
| 4 | Insert needle at 45° angle (or 90° for longer needles) | 45° for thin individuals, 90° for thicker SubQ |
| 5 | Inject slowly — 10 seconds for 0.1 mL | Slow injection reduces pressure and pain |
| 6 | Withdraw needle at same angle as entry | Don't twist or drag |
| 7 | Apply light pressure with swab | Do not rub — spreads the injection |
Troubleshooting Common Issues
**Bleeding after injection:** Usually a minor capillary nick. Apply light pressure for 30 seconds. Normal and not a concern unless it doesn't stop.
**Pain or burning during injection:** Usually caused by alcohol that hasn't fully dried, injecting too fast, or a bent needle tip (always use fresh needles). Cold peptide solution can also cause brief discomfort — let the syringe warm to room temperature.
**Raised lump after injection:** Normal. A small bleb of fluid under the skin will absorb within 15–30 minutes. Rubbing it doesn't help and may cause bruising.
**Bruising:** Common, especially in abdominal site. Usually from minor vessel contact. Rotate sites to allow recovery. Not dangerous.
**Air bubbles in syringe:** Tap the syringe gently and push the plunger slightly to expel. In SubQ injections, small bubbles are not dangerous (unlike IV injection), but good practice to remove them.
Research-Grade Sourcing
WolveStack partners with Ascension Peptides for independently third-party tested research compounds with published COAs. The links below go directly to the relevant products.
For research purposes only. Affiliate disclosure: WolveStack earns a commission on qualifying purchases at no additional cost to you.
Also Available at Apollo Peptide Sciences
Apollo Peptide Sciences carries independently tested research-grade compounds. Products ship from the USA with published purity certificates.
For research purposes only. Affiliate disclosure: WolveStack earns a commission on qualifying purchases at no additional cost to you.
Safety and Side Effect Considerations
Common Side Effects:
- Injection site reactions: Mild pain, redness, or swelling at the injection site is the most common side effect of subcutaneous injection. These reactions are typically self-limiting and resolve within 24-48 hours. Using insulin-gauge needles (29-31G) and allowing the solution to reach room temperature before injection can minimize discomfort.
- Bruising: Small subcutaneous bruises may form, particularly in areas with more superficial blood vessels. Gentle pressure after withdrawal and avoiding aspirin or NSAIDs before injection can reduce bruising.
- Lipodystrophy: Repeated injections at the same site can cause lipodystrophy — localized changes in subcutaneous fat tissue that appear as either indentations (lipoatrophy) or lumps (lipohypertrophy). Systematic rotation of injection sites prevents this complication.
- Itching or hives: Localized allergic-type reactions may occur at the injection site. If localized, these are generally mild. Widespread hives or itching suggest a systemic allergic reaction requiring medical attention.
Serious Safety Concerns: The primary serious risks of subcutaneous injection relate to infection and allergic reactions. Non-sterile technique can introduce bacteria, leading to injection site abscesses or cellulitis. In rare cases, serious systemic infections can develop. Anaphylactic reactions to injected compounds, while rare, require immediate emergency medical treatment.
Contraindications: Subcutaneous injection should be avoided in areas of active skin infection, inflammation, or damage. Individuals with known allergies to the compound being injected, or to components of the reconstitution solution (such as benzyl alcohol in bacteriostatic water), should not proceed without medical guidance. Those with severe bleeding disorders should consult their physician before subcutaneous injection.
Risk Mitigation Best Practices: Always wash hands thoroughly before preparing injections. Swab injection sites and vial stoppers with alcohol and allow to dry completely. Use new, sterile needles and syringes for each injection — never reuse or share. Inspect solutions for particulate matter, cloudiness, or discoloration before injecting. Keep a log of injection sites to ensure proper rotation.
Signs Requiring Medical Attention: Seek medical care for increasing redness, warmth, swelling, or pain at the injection site lasting beyond 48 hours; any pus or drainage; red streaks extending from the injection site; fever or systemic symptoms following injection; or signs of allergic reaction including hives, facial swelling, difficulty breathing, or lightheadedness.
This guide provides general educational information about subcutaneous injection technique. It does not constitute medical advice. Proper training from a qualified healthcare professional is recommended before performing self-injection. Always consult a healthcare provider before administering any injectable compound, and never use research chemicals labeled "not for human consumption" without understanding the associated risks.
Trusted Research-Grade Sources
Below are the two vendors we recommend for research peptides — both publish independent third-party Certificates of Analysis (COAs) and ship internationally. Affiliate links: we earn a small commission at no extra cost to you (see Affiliate Disclosure).
Particle Peptides
Independently HPLC-tested, transparent COAs, comprehensive product range.
Browse Particle Peptides →Limitless Life Nootropics
Premium research peptides with strong customer support and verified purity.
Browse Limitless Life →Frequently Asked Questions
28–31 gauge is standard. 29G is the most common choice — thin enough to cause minimal pain, thick enough that drawing from a vial doesn't take forever. 31G is the thinnest commonly available and is virtually painless but draws slower. Avoid anything below 28G for SubQ — unnecessary pain and tissue trauma.
SubQ injections target the fatty tissue directly under the skin, roughly 4–8mm deep depending on body composition. A 5/16 inch (8mm) needle inserted at 45° reaches the SubQ layer on most people. Thinner individuals may prefer a shallower angle; more substantial SubQ tissue allows 90° insertion.
Not recommended. Repeated injection at the same site causes lipohypertrophy — hardened fatty lumps that reduce absorption consistency. Rotate between at least 3–4 sites. Mark a rotation schedule if you're injecting multiple times daily.
No. Aspiration (pulling back the plunger to check for blood before injecting) is no longer recommended for SubQ injections and was never necessary for IM injections at most sites. Major blood vessels don't run through typical SubQ injection sites. Current best practice is to skip aspiration for SubQ.
SubQ goes into fatty tissue just below the skin (slower absorption, more consistent plasma levels). IM goes directly into muscle tissue (faster absorption, sharper peak). Most peptide protocols use SubQ. IM is sometimes used for TB-500 loading doses or when faster systemic absorption is specifically desired. SubQ is lower risk and appropriate for most peptide research protocols.
Generally yes, if both are reconstituted in BAC water and neither is known to be chemically incompatible with the other. BPC-157 and TB-500 are commonly injected together. CJC-1295 and Ipamorelin are routinely combined. Mixing should be done immediately before injection, not stored pre-mixed. When in doubt, use separate syringes.